BPC-157 · TB-500 · GHK-Cu · NAD+ · Semax · Selank · Retatrutide — independently tested

SKU: evexia-reta Categories: ,

Retatrutide

Retatrutide is an investigational synthetic peptide and a first-in-class triple-hormone-receptor agonist designed for the treatment of obesity and type 2 diabetes. It mimics the actions of three natural gut hormones: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon.

Price range: $95.99 through $299.99

For research use only. Not for human consumption. Not FDA approved.

About this compound

Retatrutide (LY3437943) is an investigational synthetic peptide functioning as a first-in-class triple agonist at GLP-1, GIP, and glucagon receptors simultaneously. Its tripartite receptor activity profile distinguishes it from dual-agonist compounds and makes it a subject of active investigation in metabolic receptor pharmacology.

Compound Specifications

  • Molecular Weight: ~4,718 Da
  • CAS: 2381090-38-4
  • Purity: ≥99.002–99.569% by lot (HPLC + MS verified)
  • Form: Lyophilized powder
  • Storage: −20°C, protected from light and moisture
  • Reconstitution: Bacteriostatic water or sterile water
  • Available sizes: 10mg, 20mg, 50mg, 60mg

Research Context

Research applications include comparative receptor agonism studies, energy expenditure modeling, and investigation of tripartite incretin-glucagon axis interactions. Batch-specific COAs available for each size.

For research and laboratory use only. Not for human or animal consumption. Research Use Only.